2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2302 Immunoglobulin isotype shapes serum mass spectrometry kinetics without altering its prognostic value in multiple myeloma

Noemi Puig, PhD, Cristina Agullo, MD, PhD2, Sergio Castro, MSc3, Bruno Paiva, PhD4, Maria Teresa Cedena Romero, MD5, Edibe Sevde Eker, MD6, Joaquin Martinez-Lopez Sr, MD, PhD7, Albert Oriol Sr, MD8, María Jesús Jesús Blanchard, PhD9, Rafael Rios Tamayo, MD, PhD10, Maria Belen Inigo Rodriguez, MD11, Sunil Lakhwani, MD, PhD12, Javier De La Rubia, MD, PhD13, Veronica Gonzalez-Calle, MD, PhD14, Valentin Cabanas Perianes, MD15, Miguel Paricio16, Jose Maria Moraleda, MD, PhD17, Virginia Fernandez-Chanca18, Paula Sanchez-Garcia19, Joan Bargay, MD, PhD20, Laura Rosiñol Dachs Sr, MD, PhD21, Joan Batista Blade Creixenti Sr, MD22, Jesus San-Miguel Sr, Md, PhD23, Juan-Jose Lahuerta Palacios, MD, PhD24, Maria-Victoria Mateos Jr, MD, PhD25
1 Department of Hematology, University Hospital of Salamanca, IBSAL, IBMCC-CSIC, CIBERONC, Salamanca, Spain
2 Clinical Laboratory, University Hospital of Salamanca, Salamanca, Spain
3 Clinical Laboratory, University Hospital of Salamanca, Salamanca, Spain
4 Centre for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Navarra, Spain
5 Hospital Universitario 12 de Octubre, CIBER-ONC CB16/12/00369, CNIO, Madrid, Spain
6 Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey
7 Hospital Universitario 12 de Octubre, CIBER-ONC CB16/12/00369, CNIO, Madrid, Spain
8 Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Barcelona, Spain
9 Hospital Ramón y Cajal, Madrid, Spain
10 University Hospital Puerta de Hierro, Madrid, Spain
11 Hospital Clínico San Carlos, Madrid, Spain
12 Hospital Universitario de Canarias, Santa Cruz de Tenerife, Santa Cruz de Tenerife, Spain
13 Hospital Universitari i Politècnic La Fe, Valencia, Spain
14 Department of Hematology, University Hospital of Salamanca, IBSAL, IBMCC-CSIC, CIBERONC, Salamanca, Spain
15 Department of Hematology, IMIB-Virgen de la Arrixaca University Hospital. University of Murcia, Murcia, Spain
16 Hospital Universitario Lozano Blesa, IIS Aragón, Zaragoza, Spain
17 Department of Hematology, IMIB-Virgen de la Arrixaca University Hospital. University of Murcia, Murcia, Spain
18 Clinical Laboratory, University Hospital of Salamanca, Salamanca, Spain
19 Clinical Laboratory, University Hospital of Salamanca, Salamanca, Spain
20 Hospital Universitario Son LLatzer, Mallorca, Spain
21 Hospital Clinic, Barcelona, Spain
22 Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain
23 Centre for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Navarra, Spain
24 Hospital Universitario 12 de Octubre, CIBER-ONC CB16/12/00369, CNIO, Madrid, Spain
25 Department of Hematology, University Hospital of Salamanca, IBSAL, IBMCC-CSIC, CIBERONC, Salamanca, Spain

Background: Serum mass spectrometry (MS) detects monoclonal proteins below the sensitivity of immunofixation, but its greater sensitivity creates a clinically relevant dilemma: whether low-level positivity after treatment reflects viable residual disease or persistence of previously secreted protein. Because monoclonal protein classes have distinct serum kinetics, we investigated whether isotype influences longitudinal patterns of MS positivity and modifies their association with progression-free survival (PFS).

Methods: Serial serum samples from transplant-eligible patients enrolled in GEM2012MENOS65 were analyzed centrally by quantitative immunoprecipitation MALDI-TOF MS using the EXENT platform and independently validated in GEM2017FIT. Analyses were restricted to IgG, IgA, and light-chain (LC) MM. MS positivity was assessed at 6-12, >12-24, >24-48, and >48 months from diagnosis, selecting the first evaluable sample per patient in each window. A logistic model with patient-clustered robust standard errors tested the isotype-by-time interaction. Landmark PFS was measured from the selected sample date after excluding patients with prior progression. Cox models compared MS-positive versus MS-negative patients, tested MS-by-isotype interactions, and, in a landmark-stratified supermodel with patient-clustered robust variance, MS-by-landmark interactions within each isotype. Negative-to-positive conversion was defined as a positive result after a previous negative result.

Results: 1,803 samples from 330 GEM2012MENOS65 patients were analyzed (median, 4; IQR, 3-7 samples per patient). First, we confirmed that PFS did not differ significantly across immunoglobulin isotypes (log-rank P=.84). Overall MS positivity declined from 58.2% at 6-12 months to 37.8% at >12-24 months and 28.6% at >24-48 months, and rising to 29.5% beyond 48 months. Longitudinal kinetics differed by isotype (isotype-by-time interaction, P=.036). IgG showed a continuous decline in population-level positivity (62.0%, 44.2%, 31.0%, and 23.1%), whereas IgA declined initially and then increased at later landmarks (60.8%, 34.4%, 36.0%, and 43.9%). LC MM had the lowest early positivity rates (33.3%, 21.2%, and 19.0%), with an increase beyond 48 months (29.4%).

MS positivity was associated with shorter PFS at every landmark, with HRs of 1.70 (95% CI, 1.13-2.54), 1.58 (95% CI, 1.12-2.23), 2.62 (95% CI, 1.63-4.19), and 4.66 (95% CI, 2.27-9.57), respectively (all P≤.011). Although HRs were numerically larger after 24 months when formally tested, the prognostic effect did not significantly vary across landmarks within IgG, IgA, or LC MM (MS-by-landmark interaction P=.074, .422, and .415, respectively). No significant MS-by-isotype interaction was detected at any landmark (P=.102, .312, .446, and .141), providing no statistical evidence that isotype modified the prognostic association of MS positivity.

Among 242 patients who achieved MS negativity and had subsequent follow-up, 56 (23.1%) later became MS-positive. Reappearance of the original M-protein was associated with subsequent progression (OR, 2.84; 95% CI, 1.48-5.56; P=.001), while the interval from conversion to progression ranged from 6.3 to 10.8 months across isotypes and did not differ by isotype (P=.41). In the independent validation cohort (GEM2017FIT), 107 of 275 patients (38.6%) were MS-positive at the >12–24-month landmark. MS positivity remained associated with shorter PFS (HR, 2.81; 95% CI, 1.69–4.69; P<.001), with no evidence of an MS-by-isotype interaction (P=.268).

Conclusions: Although immunoglobulin isotype shapes serum mass spectrometry kinetics, MS positivity retains consistent prognostic value across isotypes and disease time points. M-protein reappearance identifies patients at increased risk of progression and represents a clinically meaningful biomarker during longitudinal disease monitoring.
Noemi Puig, PhD: Amgen - Honoraria; Sanofi - Honoraria; BMS - Honoraria; GSK - Honoraria; BD/Waters - Honoraria; Regeneron - Honoraria; Menarini - Honoraria; Kite - Honoraria; Thermofisher - Honoraria; Johnson & Johnson - Honoraria; Abbvie - Honoraria; PFIZER - Honoraria; Oncopeptides - Honoraria; Takeda - Honoraria; PFIZER - Research Funding; Amgen - Research Funding; Thermofisher - Research Funding; Takeda - Research Funding; Johnson & Johnson - Research Funding; BMS - Research Funding; GSK - Research Funding; Johnson & Johnson - Consultancy (Includes expert testimony); Menarini - Consultancy (Includes expert testimony); Thermofisher - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); PFIZER - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); BD/Waters - Consultancy (Includes expert testimony)